Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent of -10.2% in Q4 2025.
- How has Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent changed year-over-year?
- Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent decreased by 55.6% year-over-year, from -6.5% to -10.2%.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent mean?
- The impact of changes in the valuation allowance for deferred tax assets on the effective tax rate, expressed as a percentage. This metric indicates how adjustments to tax asset recoverability expectations influence the company's reported tax rate.